It has been discovered that EGCG can limit the proliferation of chronic myeloid leukemia cells by inducing apoptosis via the suppression of the BCR/ABL oncoprotein and managing its downstream pathways, such as p38-MAPK/JNK and JAK2/STAT3/AKT [182]. Here, MAPK1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.